NCT06208878

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR T Cellular Therapies

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 70 (estimated)
• Sponsor: CRISPR Therapeutics AG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

Detailed description

All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.

Conditions

• Hematologic Malignancy
• Solid Malignancy

Interventions

Type	Name	Description
OTHER	Non Interventional	Safety and Efficacy Assessment

Timeline

• Start date: 2023-11-22
• Primary completion: 2038-08-01
• Completion: 2038-08-01
• First posted: 2024-01-17
• Last updated: 2025-08-14

Locations

22 sites across 4 countries: United States, Australia, Canada, Germany